Pooled data from AURORA 1 and 2 show that Voclosporin maintained reductions in UPCR vs. control over the 3-yr treatment period in pts with #lupus nephritis #ACR22 @RheumNow ABST#1653 https://t.co/C4n6Yb8bdC

Nestor et al. HCQ <5mg/kg day assoc increased hospitalisation for SLE flare. aOR 4.41 (95% CI 1.50-12.98) @RheumNow #ACR22 Abstr#1654 https://t.co/I4bTu2DWaR https://t.co/jpOwHUTenk

• Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizat…

Are we giving enough HCQ?🤔 Findings from the study of Dr J Nestor show that ⬇️dose HCQ (</= 5mkd or <400mg/day) is associated w/ ⬆️hospitalizations for #lupus (adj. OR 4.41; 3.48) #ACR22 @RheumNow ABST#1654 @rheumarhyme #ACRBest https://t.co/XCoZgbdOim

What’s new w #classification for #APS? You don’t have to have 2 positive tests disseminated in time. BUT remember the the labs for anticardiolipin are shockingly variable btwn centres. @RheumNow #ACR22 https://t.co/NTqQ6h7fws

• https://twitter.com/ericdeinmd/status/1592017355458379776

Chen et al. Appendicitis associated increased risk incident SLE in population-based case-control study from Taiwan. HR 2.04 @RheumNow #ACR22 Abstr#1750 https://t.co/L9dTpMdHNP https://t.co/mEHeL6JnuE

• Association Between Appendicitis and the Risk of Systemic Lupus Erythematosus: …

#ACR2022 L07: Telitacicept - anti-BlyS and APRIL in SLE 335 pts P3 52 wk study TEL 160 mg SQ q7d vs PBO 83% SRI4 response in TEL vs 38% PBO (p<0.001) As early as w4, sustained to w52 Most common AEs: URIs, decr IgG/IgM, injxn site rxn, UTI @RheumNow #ACRBest https://t.co/UpEwEaonDO

A Novel Treatment Response Measurement Tool for Lupus Dr. Dao discusses abstract 2054 with Dr. Morand at the #ACR22 Convergence. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process. https://t.co/iqqyI953Vz https://t.co/taUjTHsrJ2

• https://bit.ly/3hGxCEv

Even young SLE patients are still at high risk of severe COVID: - in general pop, age is key factor - in SLE, risk is high across age groups (maybe due to both meds & disease) - vaccination makes a big diff but SLE pts still at high risk ABST1591 @CCalabreseDO #ACR22 @RheumNow https://t.co/ra1F79ITn3

Wu et al Phase 3 RCT of Telitacicept (targets BlyS and APRIL) in SLE. Primary endpoint met at week 52! SRI(4) 67% vs 33% or 83% vs 38% (P<0.001 for both) depending on how you want to slice it. @RheumNow #ACR22 Abstr#L07 https://t.co/nnKr4AU8Jk https://t.co/9BVF6OljFQ

• Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimula…